Boston, MA 04/02/2014 (usastockreports) – Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has announced it has begun pivotal global phase 2 trial for AP26113, for patients suffering from metastatic Non-small cell Lung Cancer, previously treated with Crizotinib. The ALTA trial will try to find out the efficacy as well as safety levels for AP26113 in refractory NSCLC patients who have tested positive of anaplastic lymphoma oncogene.
Preliminary results from 120 patients who have already undergone Phase ½ trial has provided positive insight on the efficacy and safety levels of AP26113, as well as its profile at different dose levels. Phase 2 trial is expected to give Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) further information on how to substantiate various findings to allow for usage in patients suffering from brain metastases.
Trial design and Statistical analysis
A total of 220 patients with ALK +NSCLC will be randomized with either of them receiving 90mg of AP26113 once per day continuously. Primary `endpoint for ALTA trial will try to find out the objective response rate as measured in RECIST criteria with secondary endpoints expected to include time for response, duration of response as well as its safety cap and tolerability. The test will also try to ascertain the quality of life under the product.
Ariad may be acquired by Jazz Pharmaceuticals
The rumor mill is ablaze on news that Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) may be in line to be acquired by Jazz Pharmaceuticals with the latter thought to be willing to pay up to $20 a share, this essentially values the company at $3.6 billion. The news caused the company stock to rally in the market by highs of 5.8%.
The oncological market continues to be one of the fastest growing therapeutic as most of the pharmaceutical company’s continue to fight for a market share through the development of new drugs.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) is down by 3.23% and trading close to $8.24.